HIGHLIGHTS
- who: Jonathan T. Sims from the Eli Lilly and Company, Lilly Corporate Center, India have published the paper: Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients, in the Journal: (JOURNAL)
- future: Research into the mechanism of action of corticosteroid-reduced IgG levels will need to occur but in this study there was no detrimental impact on antibody responses to COVID19 infection.
SUMMARY
Analytes elevated in baseline COVID-19, FGF21, CCL3, CCL4, CEACAM8, CCL13/MCP4, IL-19, IL15RA, ANGPT1, MMP7, and CXCL9 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.